Sanofi is a French multinational pharma company with leading positions in immunology (Dupixent), rare diseases, and vaccines. The company is transforming from a generalist to a focused immunology and rare disease leader.
Immunology, Rare Diseases, Vaccines, Oncology
5-year financial trajectory
Business segment breakdown
Key product revenue comparison
Geographic revenue split
| Product | Indication | Revenue |
|---|---|---|
| Dupixent (dupilumab) | Immunology | $10.8B |
| Aubagio (teriflunomide) | MS | $2.0B |
| Lantus (insulin glargine) | Diabetes | $2.5B |
| Toujeo (insulin glargine) | Diabetes | $1.5B |
| Sarclisa (isatuximab) | Oncology (MM) | $0.4B |
Sanofi is the #7 pharma company. Dupixent (co-promoted with Regeneron) is the primary growth engine. The company is investing to become an immunology and rare disease specialist.
Revenue projected to grow to $48B+ by 2026, driven by Dupixent expansion (COPD, new indications). Pipeline of BTK inhibitors (tolebrutinib, rilzabrutinib) and novel immunology assets (amlitelimab) represent next wave.
Sanofi 2023 Annual Report (Form 20-F). Revenue and financial data from SEC filings (Form 10-K/20-F). Pipeline data from company R&D presentations and ClinicalTrials.gov. Market analysis by Medifirm Intelledge Global.